Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Metolazone | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Metolazone | hsa00500 | Starch and sucrose metabolism | 1.34E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Metolazone | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Metolazone | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Metolazone | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Metolazone | hsa00730 | Thiamine metabolism | 3.83E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Metolazone | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Metolazone | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Metolazone | hsa01523 | Antifolate resistance | 1.68E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | Metolazone | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | | Metolazone | hsa03013 | RNA transport | 5.01E-03 | 12 | P52298, O14893, P61326, P38919, P37198, Q7Z3B4, P35658, Q14152, P55884, O75822, P78345, Q9Y6A5 | NCBP2, GEMIN2, MAGOH, EIF4A3, NUP62, NUP54, NUP214, EIF3A, EIF3B, EIF3J, RPP38, TACC3 | More | | Metolazone | hsa04064 | NF-kappa B signaling pathway | 4.09E-03 | 8 | P10415, O00463, Q04759, Q9UDY8, Q16548, Q13315, P24522, P09341 | BCL2, TRAF5, PRKCQ, MALT1, BCL2A1, ATM, GADD45A, CXCL1 | More | | Metolazone | hsa04071 | Sphingolipid signaling pathway | 6.65E-04 | 7 | P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | | Metolazone | hsa04080 | Neuroactive ligand-receptor interaction | 1.00E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21730, P07550 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, ADRB2 | More | | Metolazone | hsa04110 | Cell cycle | 6.63E-04 | 6 | P06493, O60566, P30304, P33981, P42773, P01106 | CDK1, BUB1B, CDC25A, TTK, CDKN2C, MYC | More | | Metolazone | hsa04140 | Autophagy - animal | 3.19E-02 | 4 | P22694, Q14643, P10415, Q04759 | PRKACB, ITPR1, BCL2, PRKCQ | More | | Metolazone | hsa04145 | Phagosome | 4.48E-02 | 5 | Q15080, P05164, O60603, P35443, P13765 | NCF4, MPO, TLR2, THBS4, HLA-DOB | More | | Metolazone | hsa04146 | Peroxisome | 2.42E-02 | 5 | O43933, P56589, Q9UKG9, O75521, P33121 | PEX1, PEX3, CROT, ECI2, ACSL1 | More | | Metolazone | hsa04210 | Apoptosis | 3.44E-02 | 7 | Q13315, P10415, O76075, P24522, Q16548, P43234, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ITPR1 | More | | Metolazone | hsa04330 | Notch signaling pathway | 2.77E-02 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | | Metolazone | hsa04340 | Hedgehog signaling pathway | 3.09E-02 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | | Metolazone | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Metolazone | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | | Metolazone | hsa04612 | Antigen processing and presentation | 4.48E-02 | 5 | P13765, P26715, P26717, Q13241, P01732 | HLA-DOB, KLRC1, KLRC2, KLRD1, CD8A | More | | Metolazone | hsa04613 | Neutrophil extracellular trap formation | 1.20E-04 | 17 | O60603, P05164, P08246, Q9UM07, Q6FI13, Q93077, P62807, O60814, P68431, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Metolazone | hsa04640 | Hematopoietic cell lineage | 4.95E-02 | 3 | P01730, P06127, P09564 | CD4, CD5, CD7 | More | | Metolazone | hsa04650 | Natural killer cell mediated cytotoxicity | 3.67E-03 | 9 | P78314, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | Metolazone | hsa04657 | IL-17 signaling pathway | 4.98E-02 | 6 | O00463, Q16539, P14780, Q9UJX4, P80188, P01375 | TRAF5, MAPK14, MMP9, ANAPC5, LCN2, TNF | More | | Metolazone | hsa04658 | Th1 and Th2 cell differentiation | 3.52E-05 | 9 | Q04759, P20963, P09693, Q16539, P06239, Q14765, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, MAPK14, LCK, STAT4, GATA3, TBX21, HLA-DOB | More | | Metolazone | hsa04659 | Th17 cell differentiation | 4.24E-04 | 9 | Q04759, Q16539, P06239, P13765, P14778, Q9UL17, P23771, P09693, P20963 | PRKCQ, MAPK14, LCK, HLA-DOB, IL1R1, TBX21, GATA3, CD3G, CD247 | More | | Metolazone | hsa04660 | T cell receptor signaling pathway | 1.00E-02 | 7 | Q9UDY8, Q04759, P10747, Q08881, P20963, P09693, P01732 | MALT1, PRKCQ, CD28, ITK, CD247, CD3G, CD8A | More | | Metolazone | hsa04922 | Glucagon signaling pathway | 4.23E-02 | 4 | P22694, P06737, Q12778, Q14643 | PRKACB, PYGL, FOXO1, ITPR1 | More | | Metolazone | hsa04924 | Renin secretion | 1.04E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | Metolazone | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.23E-02 | 4 | Q14643, P22694, P23771, P10415 | ITPR1, PRKACB, GATA3, BCL2 | More | | Metolazone | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Metolazone | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | | Metolazone | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Metolazone | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | | Metolazone | hsa05143 | African trypanosomiasis | 1.31E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Metolazone | hsa05144 | Malaria | 1.44E-03 | 6 | P60033, P69905, P68871, O60603, P35443, P26718 | CD81, HBA2, HBB, TLR2, THBS4, KLRK1 | More | | Metolazone | hsa05169 | Epstein-Barr virus infection | 4.41E-02 | 8 | P13765, Q13547, O00463, Q16539, P24522, O60603, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, MAPK14, GADD45A, TLR2, CD3G, CD247 | More | | Metolazone | hsa05202 | Transcriptional misregulation in cancer | 1.40E-03 | 15 | Q12778, Q15532, Q13315, P41732, P14780, P27930, P14923, Q16548, Q13077, O15550, P35226, P05164, P08246, Q9C0K0, P24522 | FOXO1, SS18, ATM, TSPAN7, MMP9, IL1R2, JUP, BCL2A1, TRAF1, UTX, BMI1, MPO, ELA2, BCL11B, GADD45A | More | | Metolazone | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Metolazone | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Metolazone | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 3.07E-03 | 7 | P20963, P09693, P06239, O60603, P10747, Q04759, Q16539 | CD247, CD3G, LCK, TLR2, CD28, PRKCQ, MAPK14 | More | | Metolazone | hsa05321 | Inflammatory bowel disease | 1.17E-03 | 5 | O60603, P13765, Q14765, Q9UL17, P23771 | TLR2, HLA-DOB, STAT4, TBX21, GATA3 | More | | Metolazone | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Metolazone | hsa05323 | Rheumatoid arthritis | 1.60E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | | Metolazone | hsa05332 | Graft-versus-host disease | 3.45E-03 | 4 | P13765, P10747, P26715, Q13241 | HLA-DOB, CD28, KLRC1, KLRD1 | More | | Metolazone | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | |